| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | NEKTAR THERAPEUTICS, INC. CM | Apr 30, 2026 | |
| Sell | NEKTAR THERAPEUTICS CMN | Nov 10, 2021 | |
| Sell | NEKTAR THERAPEUTICS INC CMN | Sep 2, 2021 | |
| Sell | Nektar Therapeutics | Apr 9, 2021 | |
| Sell | NEKTAR THERAPEUTICS CMN | Jul 14, 2020 | |
| Sell | NEKTAR THERAPEUTICS CMN | Apr 20, 2020 | |
| Buy | Nektar Therapeutics Cl. B | Mar 31, 2020 | |
| Sell | NEKTAR THERAPEUTICS CMN | Mar 23, 2020 | |
| Sell | National Bank Holdings | Dec 24, 2019 | |
| Sell | National Bank Holdings | Dec 12, 2019 |
This page tracks congressional stock trading activity in Nektar Therapeutics (NKTR) in the Healthcare sector. Disclosed Capitol has indexed 49 disclosed congressional trades involving NKTR. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of May 2026 — Disclosed Capitol has tracked 49 disclosed congressional trades in Nektar Therapeutics (NKTR) — 25:22 sell-heavy ratio — led by Michael McCaul (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Apr 30, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Nov 10, 2021 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Sep 2, 2021 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Apr 9, 2021 | Sara Jacobs | D | Sale | $15,001 - $50,000 |
| Jul 14, 2020 | Ted Yoho | R | Sale | $1,001 - $15,000 |
| Apr 20, 2020 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Mar 31, 2020 | Kurt Schrader | D | Purchase | $1,001 - $15,000 |
| Mar 23, 2020 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Dec 24, 2019 | Michael McCaul | R | Sale | $1,001 - $15,000 |
| Dec 12, 2019 | Michael McCaul | R | Sale | $1,001 - $15,000 |
Across the 49 disclosed congressional trades in Nektar Therapeutics (NKTR), members of Congress have reported 22 buys and 25 sells. The average 30-day alpha vs. the S&P 500 is -1.81%.
As of July 2026, corporate insiders at Nektar Therapeutics have filed 6 SEC Form 4 transactions in NKTR over the past 12 months — including 4 sells worth $518K.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-07-24 | Zalevsky Jonathan — Chief R&D Officer | Award | — |
| 2026-07-24 | ROBIN HOWARD W — President & CEO | Award | — |
| 2026-06-15 | Zalevsky Jonathan — Chief R&D Officer | Sale | $336K |
| 2026-02-18 | Zalevsky Jonathan — Chief R&D Officer | Sale | $13K |
| 2026-02-18 | ROBIN HOWARD W — President & CEO | Sale | $31K |
| 2026-01-20 | Zalevsky Jonathan — Chief R&D Officer | Sale | $138K |
| 2025-12-22 | Zalevsky Jonathan — Chief R&D Officer | Award | — |
| 2025-12-22 | Zalevsky Jonathan — Chief R&D Officer | Award | — |
| 2025-12-22 | ROBIN HOWARD W — President & CEO | Award | — |
| 2025-12-22 | ROBIN HOWARD W — President & CEO | Award | — |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
For fiscal year 2025, Nektar Therapeutics reported revenue of $98.4M and net income of -$119.0M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $10.1M, net income -$40.6M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.